Enzo Biochem, Inc. ENZ was a big mover last session, as the company saw its shares rise above 5% on the day. The upside was driven by the company’s improved results for the second-quarter fiscal 2017. Also, this led to far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $6.45 to $7.05 in the past one-month time frame.
The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Enzo Biochem currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the Medical – Biomedical and Genetics industry is Anthera Pharmaceuticals, Inc. ANTH, which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ENZ going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
Anthera Pharmaceuticals, Inc. (ANTH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
March 21, 2017 at 06:23PM
http://ift.tt/2mLlT5u
from Zacks Equity Research
http://ift.tt/2mLlT5u
No comments:
Post a Comment